Representative Greg Murphy, a Republican from North Carolina and a practicing urological surgeon, officially introduced the Every Dollar Counts Act this Tuesday, marking a significant legislative attempt to overhaul how out-of-pocket prescription drug costs are tracked and credited by health insurance providers. The proposed legislation seeks to mandate that all out-of-pocket expenditures for covered prescription medications be applied toward a patient’s annual deductible and maximum out-of-pocket limits, regardless of the platform or pharmacy through which the drugs are acquired. This move aims to bridge a growing gap in the healthcare market where patients find lower prices through direct-to-consumer (DTC) platforms but are penalized by their insurance companies for doing so.
Under current insurance frameworks, many health plans only count drug expenditures toward a patient’s deductible if the medication is purchased through "designated plan channels," which typically include specific preferred retail pharmacies or the insurance provider’s own mail-order pharmacy services. As the pharmaceutical landscape shifts toward digital-first, manufacturer-direct, and cash-pay models, Representative Murphy argues that the current system forces patients into a "pay twice" scenario: once for the discounted medication and again through their insurance premiums and unmet deductibles that fail to reflect their actual healthcare spending.
The Shift Toward Direct-to-Consumer Pharmaceutical Platforms
The Every Dollar Counts Act arrives at a time of rapid transformation in the way Americans access prescription drugs. Traditionally, the supply chain for medication involved a complex web of manufacturers, wholesalers, pharmacy benefit managers (PBMs), and retail pharmacies. This complexity often resulted in high list prices and opaque "rebate" systems that did not always translate into savings for the end consumer.
In response, pharmaceutical giants and tech-driven startups have launched direct-to-consumer platforms designed to bypass the traditional "middlemen." Notable examples highlighted in Murphy’s announcement include Eli Lilly’s LillyDirect and Novo Nordisk’s NovoCare. These platforms allow patients to obtain prescriptions for chronic conditions—ranging from diabetes to obesity—directly from the manufacturer or through integrated telehealth partners. Similarly, telehealth companies like Hims & Hers and Ro have gained significant market share by offering transparent, often lower, cash-pricing for common medications.
While these platforms often offer medications at a fraction of the price found at traditional retail pharmacies—particularly for those with high-deductible health plans—the lack of "deductible credit" remains a major deterrent. If a patient spends $500 on a life-saving medication through a DTC platform, that $500 currently does not count toward the $3,000 deductible they must meet before their insurance coverage fully kicks in. Consequently, patients are often forced to choose between a cheaper upfront price that leaves their insurance status stagnant or a more expensive "in-network" price that helps them reach their coverage threshold faster.
Addressing the "Pay Twice" Penalty and Market Distortion
The core objective of the Every Dollar Counts Act is to eliminate what Murphy describes as "market distortion." By requiring insurance companies to recognize and credit these external purchases, the bill seeks to empower patients to shop for the best possible price without fear of losing their insurance progress.
"Direct-to-patient platforms have the potential to radically transform the drug marketplace, applying much-needed downward pressure on the extraordinary cost of lifesaving medicines," Representative Murphy stated in a press release accompanying the bill’s introduction. "However, patients who are set to benefit most cannot apply their expenditures on drugs purchased through these platforms to their health insurance out-of-pocket contribution requirements. By making this possible, we are putting patients first and promoting competition to drive down costs further."
From a clinical perspective, the bill addresses the issue of "fragmented access" and "delayed care." When patients are forced to navigate complex insurance networks to find an affordable pharmacy that "counts" toward their deductible, they often face delays in starting treatment. Furthermore, if a patient cannot afford the in-network price and the DTC price doesn’t help their long-term insurance goals, they may skip doses or abandon therapy entirely—a phenomenon known as primary non-adherence.
Supporting Data on Drug Costs and Patient Behavior
The necessity for such legislation is underscored by a wealth of data regarding American healthcare spending. According to a 2023 report from the Kaiser Family Foundation (KFF), approximately three in ten U.S. adults report not taking their medicines as prescribed at some point in the past year because of the cost. This includes not filling a prescription, taking an over-the-counter drug instead, or cutting pills in half.
Furthermore, data from the Peterson-KFF Health System Tracker indicates that while total out-of-pocket spending on retail prescription drugs has slowed in its rate of growth over the last decade, the burden on patients with high-deductible health plans (HDHPs) has intensified. For these individuals, the "list price" or the "negotiated rate" at a retail pharmacy is what they pay until their deductible is met. In many cases, the cash price on a platform like Mark Cuban Cost Plus Drug Company or through a manufacturer-direct portal is significantly lower than the "negotiated rate" an insurance company has established with a PBM.
The Every Dollar Counts Act would essentially force insurance companies to acknowledge the efficiency of the free market. If a patient finds a better deal outside of the insurer’s preferred network, the insurer would no longer be able to ignore that expenditure.
Chronology of Direct-to-Consumer Initiatives
The legislative push by Representative Murphy follows a series of public and private sector moves to disrupt the traditional pharmacy model:
- 2022-2023: The rise of "Cost-Plus" models, most notably the Mark Cuban Cost Plus Drug Company, begins to gain national attention by offering generic drugs with a transparent 15% markup, bypassing traditional PBM negotiations.
- January 2024: Eli Lilly launches LillyDirect, an end-to-end digital healthcare experience for patients in the U.S. living with obesity, migraine, and diabetes.
- February 2024: The Trump administration (via the TrumpRx initiative) launches a platform designed to provide discounted cash prices for brand-name drugs. While TrumpRx serves as a directory and coupon aggregator rather than a direct pharmacy, it signaled a growing political appetite for DTC solutions.
- May 2024: Major insurers and PBMs begin facing increased scrutiny from the Federal Trade Commission (FTC) regarding their "anti-competitive" practices, including how they steer patients toward their own specialty pharmacies.
- Tuesday: Representative Murphy introduces the Every Dollar Counts Act, seeking to codify patient protections into federal law.
Reactions from Advocacy Groups and Industry Stakeholders
The Council for Affordable Health Coverage (CAHC), a prominent advocacy group focused on market-based solutions to lower healthcare costs, has come out in strong support of the bill. Joel White, President of the CAHC, emphasized that affordability is the primary barrier to health equity in the United States.
"Affordability is the defining concern for Americans," White stated. "In healthcare, it determines whether patients can get the medicines and care they need to stay healthy. Congressman Murphy’s legislation helps remove barriers to that care and improve health outcomes."
However, the bill is expected to face resistance from the insurance industry and PBM trade groups. Industry lobbyists often argue that "steering" patients toward preferred pharmacies allows insurers to manage the quality of care and ensure that patients are receiving proper counseling from pharmacists. They also argue that allowing external expenditures to count toward deductibles would make it more difficult for insurers to predict costs and negotiate bulk discounts with manufacturers, potentially leading to higher premiums across the board.
Fact-Based Analysis of Broader Implications
If the Every Dollar Counts Act were to pass, the implications for the healthcare economy would be profound. First, it would likely accelerate the adoption of DTC platforms. If patients know that every dollar spent on LillyDirect or Ro counts toward their insurance limits, the primary incentive to stay within a PBM’s "preferred network" evaporates. This would force traditional retail pharmacies and PBMs to lower their prices to remain competitive.
Second, the bill could lead to a significant shift in how health plans are designed. Currently, insurers use "accumulator adjustment programs" to prevent manufacturer co-pay assistance from counting toward deductibles. While Murphy’s bill focuses on direct purchases rather than co-pay cards, it strikes at the same underlying principle: the insurer’s desire to control which dollars count toward the "out-of-pocket" finish line.
Third, the legislation could improve long-term health outcomes and reduce overall system costs. By making medications more affordable and ensuring that patients reach their maximum out-of-pocket limits sooner, the bill could lead to better management of chronic diseases. This, in turn, reduces the likelihood of expensive emergency room visits and hospitalizations resulting from untreated conditions.
Outlook for the Legislation
As a member of the House Ways and Means Committee, which has jurisdiction over many healthcare issues, Representative Murphy is well-positioned to advocate for the bill. However, in a polarized Congress, the path to becoming law remains challenging. The bill will likely need to garner bipartisan support by framing the issue as one of "patient choice" and "market competition"—themes that resonate across the political aisle.
For now, the Every Dollar Counts Act serves as a formal recognition of a new era in American pharmacy—one where the patient is no longer tethered to the rigid, often expensive channels dictated by insurance companies, but is instead empowered to seek value in a rapidly expanding digital marketplace. As the debate over drug pricing continues to dominate the national conversation, Murphy’s proposal offers a specific, technical fix to a problem that millions of Americans face at the pharmacy counter every month.
